FI86887B - Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. - Google Patents
Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. Download PDFInfo
- Publication number
- FI86887B FI86887B FI863041A FI863041A FI86887B FI 86887 B FI86887 B FI 86887B FI 863041 A FI863041 A FI 863041A FI 863041 A FI863041 A FI 863041A FI 86887 B FI86887 B FI 86887B
- Authority
- FI
- Finland
- Prior art keywords
- sequence
- amino acids
- fusion protein
- plasmid
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Claims (12)
1. Fusionsprotein, kännetecknat där-av, att det har den allmänna formeln 5 Met-Xn-D' -Y-Z, där n är noil eller 1; X är en sekvens av 1 - 12 gene-tiskt kodbara aminosyror; D' är en sekvens av ca 70 ami-10 nosyror inom aminosyrasekvensomrädet 23 - 93 hos D-pepti-den i trp-operonen i E. coli; Y är en sekvens av en eller flere genetiskt kodbara aminosyror, vilken möjliggör en avspjälkning av päföljande aminosyrasekvens Z; och Z är en sekvens av genetiskt kodbara aminosyror.
2. Fusionsprotein enligt patentkravet 1, kän netecknat därav, att n är 1 och X omfattar högst 5 aminosyror, varvid den N-terminala sekvensen i sekven-sen X företrädesvis är Lys-Ala.
3. Fusionsprotein enligt patentkravet 1 eller 2, 20 kännetecknat därav, att Y innehäller den C-terminala gruppen Met, Cys, Trp, Arg, Lys eller nägon ur grupperna (Asp)m-Pro, Glu-(Asp)m-Pro eller Ile-Glu-Gly-Arg, varvid m är 1,2 eller 3, eller bestär av dessa aminosyror eller nägon av dessa grupper.
4. Fusionsprotein enligt ett eller flere av före- gäende patentkrav, kännetecknat därav, att Z betecknar aminosyrasekvensen i humant proinsulin eller ett hirudin.
5. Förfarande för framställning av fusionsprotei-30 net enligt ett eller flere av patentkraven 1-4, kännetecknat därav, att genstrukturen, som kodar detta fusionsprotein uttrycks i en bakterievärdcell, företrädesvis i E. coli och fusionsproteinet avskiljs.
6. Förfarande enligt patentkravet 5, k ä n n e -35 tecknat därav, att i genstrukturen kodar DNA-sek- 26 8 6 8 S 7 vensen I (bilaga) för D', och/eller i genstrukturen kodar DNA-sekvensen (kodande sträng) 5' AAA GCA AAG GGC 3' för X, och/eller genstrukturen väljs sä, att fusionspro-5 telnet är olösligt, och/eller genstrukturen innefattas i fas 1 en vektor, som av trp-operonen i E. coli innehäller promotorn, operatorn och ribosombindningsstället för L-peptiden.
7. Förfarande enligt patentkravet 6, k ä n n e -10 tecknat därav, att vektorn är ett derivat av pBR322, väri avsnittet frän Hindlll-stället i position 29 tili PvuII-stället i position 2066 avlägsnats ur pBR322-DNA:t.
8. Genstruktur, kännetecknad därav, 15 att den kodar fusionsproteiner enligt patentkraven 1-4.
9. Vektor, företrädesvis ett derivat av plasmiden pBR322, väri avsnittet frän Hindlll-stället i position 29 tili PvuII-stället i position 2066 avlägsnats ur pBR322-DNA:t, kännetecknat därav, att den innehäller 20 genstrukturen enligt patentkravet 8.
10. Expressionssystem för bakterievärdceller, företrädesvis ett E, coli-system, kännetecknat därav, att det innehäller en vektor enligt patentkravet 9. 25
11. Förfarande för framställning av ett eukaryo- tiskt protein, kännetecknat därav, att man ur ett fusionsprotein enligt patentkraven 1-4 avspjälker aminosyrasekvensen Z kemiskt eller enzymatiskt.
12. Plasmid, kännetecknad därav, att 30 den är pH154/25 (figur 3), pH254 (figur 4), pH255 (figur 4), pH256 (figur 5), pH257 (figur 5), pH120/14 (figur 1), pKl50 (figur 7), pK160 (figur 8), pK170 (figur 9), pK180 (figur 10), pHl54/25* (figur 11), pH256*, vilken motsva-rar pH256 i figur 5 varur fragmentet som erhällits med 35 PvuII avlägsnats säsom visas i figur 11, pH120/14* vilken 27 868 S7 motsvarar pH120/14 i figur 1, varur fragmentet som erhäl-lits med Pvull avlägsnats säsom visas i figur 11, pK150*, som motsvarar pK 150 i figur 7, varur fragmentet som er-hällits med Pvull avlägsnats säsom visas i figur 11, 5 pK170*, som motsvarar pK170 i figur 9, varur fragmentet som erhällits med Pvull avlägsnats säsom visas i figur 11, eller plntl3 (figur 12). t
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853526995 DE3526995A1 (de) | 1985-07-27 | 1985-07-27 | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| DE3526995 | 1985-07-27 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI863041A0 FI863041A0 (fi) | 1986-07-24 |
| FI863041A FI863041A (fi) | 1987-01-28 |
| FI86887B true FI86887B (fi) | 1992-07-15 |
| FI86887C FI86887C (sv) | 1992-10-26 |
Family
ID=6276985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI863041A FI86887C (sv) | 1985-07-27 | 1986-07-24 | Fusionsprotein, förfarande för deras framställning och deras användnin g |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0211299B1 (sv) |
| JP (1) | JPH07113040B2 (sv) |
| KR (1) | KR950000299B1 (sv) |
| AT (1) | ATE50596T1 (sv) |
| AU (1) | AU595221B2 (sv) |
| CA (1) | CA1336329C (sv) |
| DE (2) | DE3526995A1 (sv) |
| DK (1) | DK172618B1 (sv) |
| ES (1) | ES2000278A6 (sv) |
| FI (1) | FI86887C (sv) |
| GR (1) | GR861957B (sv) |
| HU (1) | HU197356B (sv) |
| IE (1) | IE59127B1 (sv) |
| IL (1) | IL79522A (sv) |
| NO (1) | NO175640C (sv) |
| NZ (1) | NZ216967A (sv) |
| PT (1) | PT83065B (sv) |
| ZA (1) | ZA865556B (sv) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3738541A1 (de) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | Verfahren zur isolierung und reinigung von hirudin |
| DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| ATE80913T1 (de) * | 1986-03-12 | 1992-10-15 | Int Minerals & Chem Corp | Hybride expressionsvektoren, deren herstellung und verwendungen. |
| JPH03503596A (ja) * | 1987-06-24 | 1991-08-15 | ノボ・ノルディスク エー／エス | 蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用 |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| US5358857A (en) * | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| GR1005153B (el) * | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
| US5227293A (en) * | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| DE3942580A1 (de) * | 1989-12-22 | 1991-06-27 | Basf Ag | Verfahren zur herstellung von hirudin |
| DK0821006T3 (da) | 1996-07-26 | 2004-08-16 | Aventis Pharma Gmbh | Insulinderivater med öget zinkbinding |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| DK2201120T3 (en) | 2007-09-21 | 2014-03-17 | Cadila Healthcare Ltd | GCSF fusion protein systems which are suitable for high expression of the peptides |
| KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 ｇｌｐ－1 효능제의 병용물 |
| ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
| BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン／リキシセナチド固定比処方 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA802992B (en) * | 1979-06-01 | 1981-10-28 | Univ California | Human pre-growth hormone |
| ZA811368B (en) * | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| AU596585B2 (en) * | 1985-03-18 | 1990-05-10 | Genelabs Incorporated | Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector |
| GB8507666D0 (en) * | 1985-03-25 | 1985-05-01 | Wellcome Found | Epidermal growth factor production |
| GR860915B (en) * | 1985-04-08 | 1986-07-11 | Genetic Systems Corp | Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav |
-
1985
- 1985-07-27 DE DE19853526995 patent/DE3526995A1/de not_active Withdrawn
-
1986
- 1986-07-19 DE DE8686109945T patent/DE3669175D1/de not_active Expired - Lifetime
- 1986-07-19 EP EP86109945A patent/EP0211299B1/de not_active Expired - Lifetime
- 1986-07-19 AT AT86109945T patent/ATE50596T1/de active
- 1986-07-24 ES ES8600544A patent/ES2000278A6/es not_active Expired
- 1986-07-24 FI FI863041A patent/FI86887C/sv not_active IP Right Cessation
- 1986-07-25 IL IL79522A patent/IL79522A/xx not_active IP Right Cessation
- 1986-07-25 HU HU863100A patent/HU197356B/hu unknown
- 1986-07-25 CA CA000514682A patent/CA1336329C/en not_active Expired - Lifetime
- 1986-07-25 NO NO863000A patent/NO175640C/no unknown
- 1986-07-25 DK DK198603554A patent/DK172618B1/da not_active IP Right Cessation
- 1986-07-25 NZ NZ216967A patent/NZ216967A/xx unknown
- 1986-07-25 AU AU60565/86A patent/AU595221B2/en not_active Expired
- 1986-07-25 PT PT83065A patent/PT83065B/pt unknown
- 1986-07-25 GR GR861957A patent/GR861957B/el unknown
- 1986-07-25 ZA ZA865556A patent/ZA865556B/xx unknown
- 1986-07-25 IE IE197786A patent/IE59127B1/en not_active IP Right Cessation
- 1986-07-26 JP JP61176558A patent/JPH07113040B2/ja not_active Expired - Lifetime
- 1986-07-26 KR KR1019860006142A patent/KR950000299B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07113040B2 (ja) | 1995-12-06 |
| GR861957B (en) | 1986-11-25 |
| FI863041A0 (fi) | 1986-07-24 |
| ATE50596T1 (de) | 1990-03-15 |
| IE59127B1 (en) | 1994-01-12 |
| FI86887C (sv) | 1992-10-26 |
| DK172618B1 (da) | 1999-03-01 |
| HUT43629A (en) | 1987-11-30 |
| DK355486A (da) | 1987-01-28 |
| PT83065B (pt) | 1989-02-28 |
| DE3669175D1 (de) | 1990-04-05 |
| EP0211299B1 (de) | 1990-02-28 |
| IL79522A (en) | 1991-08-16 |
| PT83065A (de) | 1986-08-01 |
| AU6056586A (en) | 1987-01-29 |
| FI863041A (fi) | 1987-01-28 |
| EP0211299A2 (de) | 1987-02-25 |
| DE3526995A1 (de) | 1987-02-05 |
| NO863000D0 (no) | 1986-07-25 |
| IE861977L (en) | 1987-01-27 |
| EP0211299A3 (en) | 1988-06-01 |
| HU197356B (en) | 1989-03-28 |
| NO175640C (no) | 1994-11-09 |
| DK355486D0 (da) | 1986-07-25 |
| AU595221B2 (en) | 1990-03-29 |
| KR870001312A (ko) | 1987-03-13 |
| NO863000L (no) | 1987-01-28 |
| ES2000278A6 (es) | 1988-02-01 |
| NZ216967A (en) | 1988-08-30 |
| CA1336329C (en) | 1995-07-18 |
| IL79522A0 (en) | 1986-10-31 |
| KR950000299B1 (ko) | 1995-01-13 |
| NO175640B (sv) | 1994-08-01 |
| ZA865556B (en) | 1987-03-25 |
| JPS6229600A (ja) | 1987-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI86887B (fi) | Fusionsprotein, foerfarande foer deras framstaellning och deras anvaendning. | |
| IL95495A (en) | Fusion proteins their preparation and use | |
| JP2694840B2 (ja) | ポリペプチドを微生物により発現させる方法 | |
| US4366246A (en) | Method for microbial polypeptide expression | |
| EP0234888B1 (en) | Process for producing human epidermal growth factor and analogs thereof | |
| Kuliopulos et al. | Production, purification, and cleavage of tandem repeats of recombinant peptides | |
| DK172210B1 (da) | Hirudinderivater | |
| US4356270A (en) | Recombinant DNA cloning vehicle | |
| US4425437A (en) | Microbial polypeptide expression vehicle | |
| US4431739A (en) | Transformant bacterial culture capable of expressing heterologous protein | |
| US5648244A (en) | Production, purification, cleavage and use of fusion peptides | |
| CA1297813C (en) | Process for production of insulin-like growth factor i | |
| Sung et al. | Short synthetic oligodeoxyribonucleotide leader sequences enhance accumulation of human proinsulin synthesized in Escherichia coli. | |
| US6051399A (en) | Production of C-terminal amidated peptides from recombinant protein constructs | |
| US5545564A (en) | Vector for expression and secretion of polypeptide microorganism transformed by the vector and production of polypeptide with the same microorganism | |
| US4711847A (en) | Preparation of secretin | |
| Kempe et al. | Production and characterization of growth hormone releasing factor analogs through recombinant DNA and chemical techniques | |
| IE52122B1 (en) | Somatostatin or somatostatin precursors | |
| IE852440L (en) | Signal for protein transport | |
| FI97549C (sv) | Förfarande för framställning av främmande proteiner i Streptomycesceller | |
| SU1707078A1 (ru) | Рекомбинантна плазмидна ДНК рТНУЗ14, кодирующа полипептид со свойствами тимозина @ человека, рекомбинантна плазмидна ДНК рТНУ12 - промежуточный продукт дл ее конструировани и штамм бактерий ЕSснеRIснIа coLI - продуцент полипептида со свойствами тимозина @ человека | |
| NZ229748A (en) | Process of producing a protein from a precursor having an n-terminal pro by enzymatic cleavage | |
| FI97239B (sv) | Förfarande för framställning av fusionprotein | |
| KR840002106B1 (ko) | 세균숙주의 형질전환에 적합한 재조합 클로닝 베히클의 제조방법 | |
| KR840002090B1 (ko) | 폴리펩티드 헵텐을 함유하는 면역성 물질인 폴리펩티드를 제조하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: HOECHST AKTIENGESELLSCHAFT |
|
| MA | Patent expired |